Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!
Presenter:
Advertisement
Sign In
New at TCTMD? Register today!
Forgot Your Password?
Enter the email you used to register to reset your password.
Search TCTMD
cme